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The protease-activated receptor 2, expressed on ker-
atinocytes but not on melanocytes, has been ascribed
functional importance in the regulation of pigmenta-
tion by phagocytosis of melanosomes. Inhibition of
protease-activated receptor 2 activation by synthetic
serine protease inhibitors requires keratinocyte±mela-
nocyte contact and results in depigmentation of the
dark skinned Yucatan swine, suggesting a new class
of depigmenting mechanism and agents. We there-
fore examined natural agents that could exert their
effect via the protease-activated receptor 2 pathway.
Here we show that soymilk and the soybean-derived
serine protease inhibitors soybean trypsin inhibitor
and Bowman±Birk inhibitor inhibit protease-acti-
vated receptor 2 cleavage, affect cytoskeletal and cell
surface organization, and reduce keratinocyte phago-
cytosis. The depigmenting activity of these agents
and their capability to prevent ultraviolet-induced
pigmentation are demonstrated both in vitro and
in vivo. These results imply that inhibition of the pro-
tease-activated receptor 2 pathway by soymilk may
be used as a natural alternative to skin lightening.
Key words: keratinocyte/melanocyte/skin lightening/soy-
milk/STI. J Invest Dermatol 116:587±595, 2001
T
he protease-activated receptor 2 (PAR-2) (Nystedt
et al, 1994, 1995a,b) is a seven transmembrane G-
protein-coupled receptor that is activated by a serine
protease cleavage, creating a tethered ligand. Trypsin
and mast cell tryptase are the only known natural
activators of PAR-2 (reviewed in DeÂry et al, 1998; DeÂry and
Bunnett, 1999), but synthetic peptides that correspond to the newly
cleaved N-termini can also activate this receptor. SLIGRL, the
mouse PAR-2 activating peptide, is speci®c for PAR-2 and is
equipotent in the speci®c activation of the human PAR-2 receptor
(Nystedt et al, 1995b; Bohm et al, 1996).
PAR-2 is expressed in keratinocytes (Marthinuss et al, 1995;
Santulli et al, 1995), but not in melanocytes (Seiberg et al, 2000a),
and is involved in the regulation of pigmentation (Seiberg et al,
2000a, b; Sharlow et al, 2000). The pigmentary effect of PAR-2
modulation by SLIGRL or by serine protease inhibitors is possible
only when keratinocyte±melanocyte contact is established.
Melanocytes alone do not respond to PAR-2 modulating agents
with pigmentary changes (Seiberg et al, 2000a). PAR-2 activation
was shown to increase keratinocyte phagocytosis (Sharlow et al,
2000), resulting in increased melanosome ingestion and transfer
(Seiberg et al, 2000b), even in the absence of melanocytes. Serine
protease inhibitors that interfere with PAR-2 activation were
shown to reduce melanosome transfer and ingestion by keratino-
cytes, resulting in depigmentation both in vitro and in vivo (Seiberg
et al, 2000a, b). This depigmenting effect was reversible in vivo
(Seiberg et al, 2000a, b), excluding melanocyte death following
such treatments. Serine protease inhibition in epidemal equivalents
containing melanocytes led to a decrease in TRP-1 and an increase
in TRP-2 expression, suggesting reduced tyrosinase stability and a
shift from black to brown eumelanin synthesis (Seiberg et al,
2000a).
For medical and cosmetic reasons, it is often desired to alter skin
color. Currently available topical agents used to treat hyperpig-
mentation include tyrosinase inhibitors, retinoids, hydroquinones,
and melanocyte-cytotoxic agents. Unfortunately, the results of
these treatments are sometimes disappointing (reviewed in Jimbow
and Jimbow, 1998), and there is a need for more effective, safer,
and less irritating depigmenting therapies. Moreover, a move
towards ``natural'' therapies created a demand for a natural, safe,
and ef®cacious depigmenting treatment.
Two protein proteinase inhibitors were isolated from soybeans in
the early 1940s, the Kunitz-type trypsin inhibitor (soybean trypsin
inhibitor, STI) and the Bowman±Birk protease inhibitor (BBI)
(reviewed in Birk, 1985; Kennedy, 1998). STI inhibits the
proteolytic activity of trypsin (reviewed in Birk, 1985) by the
formation of a stable stoichiometric complex (reviewed in Liu,
1999). STI consists of 181 amino acid residues with two disul®de
bridges and is roughly spherically shaped (reviewed in Song and
Suh, 1998). BBI is an 8 kDa protein that inhibits trypsin and
chymotrypsin at separate reactive sites (Billings and Habres, 1992).
Data suggest that BBI has a stable conformation even after its
disul®de bonds are broken by heating and shows a pronounced
stability after treatment with acid and pepsin (Birk, 1985; Liu,
1999). STI and BBI are found only in the soybean seed, and not in
any other part of the plant (Birk, 1985). Soybean seeds have been
used in Asia for centuries as a dietary source of protein. Dietary
soybean consumption requires fermentation, which removes STI
and BBI to prevent blocking the trypsin activity needed for protein
digestion.
Here we show that soymilk and the soymilk-derived proteins
STI and BBI inhibit PAR-2 activation and thus induce skin
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depigmentation. Such agents may serve as an alternative, natural
treatment for hyperpigmentation.
MATERIALS AND METHODS
Chemicals and test materials Trypsin, STI, BBI, and L-3,4-
dihydroxyphenylalanine (DOPA) were from Sigma (St. Louis, MO). STI
and BBI were dissolved in phosphate-buffered saline (PBS, Life
Technologies, Grand Island, NY) for in vitro assays, and in liposomes
(20 mg per ml, in PBS) for in vivo assays. GDL liposomes, prepared
according to Niemiec et al (1995), comprised glycerol dilaurate,
cholesterol, polyoxyethylene-10-stearyl ether, and polyoxyethylene-9-
lauryl ether in the ratio 37.5:12.5:33.3:16.7. Soymilk was prepared as a
10% solution in deionized water. A hundred grams of soybeans (Oriental
Mascot Soybeans imported from China, NY, NY) were hydrated
overnight in 1 liter of water. Soybeans were rinsed in water and then
processed in 1 liter of water using a standard juice extractor. The milk
was collected and ®ltered through cheesecloth. The preservative
phenoxyethanol (Phenonip, NIPA Hardwicke, Wilmington, DE) was
added as 1% of the total volume and the soymilk was stored at 4°C.
Soybean paste was prepared similarly to soymilk, using the minimal
quantity of water that enabled grinding the beans.
Cells and cultures Human HaCaT keratinocytes were a generous gift
of Dr. N.E. Fusenig and were maintained in Dulbecco's modi®ed Eagle's
medium containing 10% fetal bovine serum, 4.5 mg per ml glucose,
2 mM L-glutamine, 50 U per ml penicillin, and 50 mg per ml
streptomycin (Life Technologies). Cells were maintained at <80%
con¯uency in 5% CO2 (vol/vol) and were used in experimental
procedures up to culture passage 15. Human primary melanocytes
(Clonetics, San Diego, CA, or Cascade Biologics, Portland, OR) were
maintained according to the manufacturer's instructions. To establish
keratinocyte±melanocyte cocultures, 6 3 104 melanocytes were plated in
each well of a 24 well plate and maintained according to the
manufacturer's instructions. Melanocytes were rinsed three times with
melanocyte growth medium without phorbol myristate acetate, and
keratinocytes (6 3 104) were plated to establish the cocultures in this
medium. Epidermal equivalents containing melanocytes (MelanoDerm)
were from MatTek Corporation (Ashland, MA) and were maintained
according to the manufacturer's instructions. Cocultures and equivalents
were treated for 3 d with test compounds, and assayed for cell viability
and pigment production on the fourth day. Ultraviolet (UV) irradiation
was performed with a UVB FS light source in an exposure chamber,
with plate covers removed and PBS present in the wells. UVB intensity
was measured with a UVX radiometer (UVP, San Gabriel, CA).
Equivalents were exposed to 0.1±0.12 J per cm2, once. Cell viability was
assayed using alamarBlue (Acumed International, West Lake, OH)
following the manufacturer's instructions. No change in viability was
observed following three daily treatments with soymilk, STI, or BBI,
with or without UV exposure. All in vitro experiments were performed
in triplicate, were repeated at least three times, and were assayed for
viability using alamarBlue.
Swine Dark skinned Yucatan microswine (Charles River, Maine) were
housed in appropriately sized cages in an environmentally controlled
room with a 12 h light, 12 h dark photoperiod and were supplied with
food and water ad libitum. Animal care was based on the Guide for the
Care and Use of Laboratory Animals, NIH Publication 85-23. Twenty
microliters of test compounds or GDL liposome vehicle (20 mg per ml,
in PBS) were applied topically, twice a day, 5 d per wk, for 8 or 9 wk,
on the dorsum of the swine. Treatments of individual swine were always
arranged in a head to tail order on one side, and in a tail to head order
on the other side of the animal. Biopsies were taken using standard
techniques. A minimal erythemal dose (MED) of UVB was determined
by placing a plastic template with 1 3 1 inch2 cutouts on the dorsum of
the swine. Using a UVB lamp (Model UVM-57, 302 nm lamp, UVP,
Upland, CA) placed on the template, sites were exposed to UVB with
increasing time points, every other day for 5 d. Unexposed sites were
covered with the same material as the template. One MED was
established as the dose that produces the least amount of visible
erythema. For UVB prevention studies swine were exposed to one
MED every other day for 5 d. Test compounds were applied
immediately after UVB exposure, and continued daily for 2 wk. To
prevent a possible sunscreen effect the treated sites were cleaned with
water and allowed to dry prior to each UVB exposure. Visual
observations of the tanning response were made after 2 wk, and biopsies
were taken at that time for histologic analysis. All swine studies presented
here had no visual irritation, and histologic analyses revealed no markers
of irritation or other pathologic signs.
Human skin grafted on SCID mice Human skin from patients
undergoing breast reduction was obtained with written consent within
24 h. Skin was kept in a cooled, moist microenvironment prior to
dermatoming to 0.4 mm thickness. T cell and B cell de®cient mice (Fox
Chase C.B-17-SCID, Taconic, NY), 6 wk old, were grafted with an
oval piece of skin, approximately 0.8 3 2.0 cm in size. Skin was grafted
onto a full-thickness skin defect of the shaved mouse and ®xed with 6-0
silk. Grafts were covered with Vaseline impregnated gauze and covered
Figure 1. STI and BBI reduce pigmentation in keratinocyte±
melanocyte cocultures. Cocultures were treated daily, for 3 d, with
STI or BBI (0.1%), and DOPA stained on the fourth day.
Representative culture images of untreated control (a) and STI treated
cultures (b) are shown. A computerized image analysis of the pigmented
area within the cells, relative to untreated controls, is shown in (c), p
< 0.005 (t test, 6 standard error).
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Figure 2. STI and BBI reduce pigment
deposition in epidermal equivalents
containing melanocytes. Equivalents were
treated daily, for 3 d, with STI and BBI (1%), and
formalin ®xed by the fourth day. Five micron
sections were F&M stained (a±c, control, STI, and
BBI, respectively; scale bar: 20 mm), and images
were analyzed for the pigmented area within the
tissue, relative to untreated controls (d); p < 0.001
for STI, p < 0.005 for BBI (t test, 6 standard
error). Equivalents were exposed once to UVB
(100 mJ per cm2), followed by three daily
treatments with STI (1%). Computerized image
analysis (d) shows an increase in pigment
deposition, relative to the untreated control,
following UVB exposure, which was prevented
by the STI treatment (p < 0.001, t test, 6
standard error).
Figure 3. STI and BBI reduce skin
pigmentation. Dark skinned Yucatan swine
were treated daily, for 8 or 9 wk, with increasing
concentrations of STI or BBI, in GDL liposomes
(20 mg per ml). A visual dose-responsive
lightening effect was observed (a, swine ¯ank with
STI treated sites), with occasional minimal
lightening with the liposome vehicle treatment.
F&M staining of skin biopsies from the treated
sites demonstrates reduced pigment deposition
following STI (c, 1%) or BBI (d, 1%) treatment,
relative to the untreated sites (b). Scale bar: 10 mm.
Images were analyzed for the pigmented area
within the tissues, relative to the untreated
control, to quantify the depigmenting effect (e); p
< 0.001 for STI, p < 0.005 for BBI (t test, 6
standard error).
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by occlusive dressing. Sutures were removed after 1 wk. One month
later the human grafts were treated daily, 5 d per wk, for 9 wk, with
15 ml of liposomes or STI (1.0%). At 9 wk the human skin was collected
for histologic analysis.
Histology, staining, and image analysis Sections from equivalents
and biopsies were stained with hematoxylin and eosin (H&E), DOPA
+ H&E, or Fontana±Mason (F&M), using standard procedures (Sheenan
and Hrapckak, 1980). Cocultures were brie¯y ®xed (10% buffered
formalin, 15 min), washed three times with PBS, and stained with
DOPA (0.1% in PBS, 5 h at 37°C) followed by two PBS washes and
formalin (10%, overnight) ®xation. DOPA is a substrate for tyrosinase.
F&M staining identi®es silver nitrate reducing molecules. In skin, this
nonspeci®c stain identi®es primarily melanin. At least three sections per
equivalent or biopsy, three equivalents per experiment, were processed.
Each experiment was repeated at least three times. F&M or DOPA
stained sections and DOPA stained monolayers were used for image
analysis. All images were obtained and analyzed with Image Pro Plus 3.0
software (Media Cybernetics, Silver Spring, MD). Parameters measured
were the surface area of silver deposits (F&M) or melanin deposits
(DOPA) within melanocytes and keratinocytes and the total surface area
of the tissue, and the relative pigmented area was calculated. A value of
100% was assigned to untreated controls, and values of treatment groups
were normalized to their relevant controls. In all experiments there was
no difference between PBS treated cells or equivalents and untreated
controls (not shown). Data presented are of one experiment, with
standard deviation. Data were analyzed using SigmaPlot 5.0 (SPSS
Science, Chicago, IL) and statistical analysis was performed using
SigmaStat 2.0 (SPSS Science) software. Scanning electron microscopy
(SEM) was performed as previously described (Piekos, 1989).
Phagocytosis assay Phagocytosis was quanti®ed using the Vybrant
Phagocytosis Assay (Molecular Probes) as described by Sharlow et al
(2000). Brie¯y, HaCaT cells were treated with STI, BBI, soymilk, or
PBS for 48 h and incubated for 4 h with 100 ml of ¯uorescein-labeled
Escherichia coli K-12 bioparticles; trypan blue was added to quench
extracellular ¯uorescence. Fluorescence was measured (485 nm
excitation/538 nm emission) using a SpectraMax Gemini microtiter plate
reader (Molecular Devices, Sunnyvale, CA). Data were collected using
Softmax Pro 3.0 software (Molecular Devices), and were analyzed using
SigmaPlot 5.0 (SPSS Science) and SigmaStat 2.0 (SPSS Science) software.
Each experiment was performed in six replicates and was repeated at
least three times.
Actin polymerization assay F-actin was detected using rhodamine
phalloidin following the manufacturer's instructions (Molecular Probes)
as described by Sharlow et al (2000). Rhodamine-labeled cells were
viewed by ¯uorescent microscopy (554 excitation/573 emission) using a
Nikon Optiphot-2 (Tokyo, Japan).
Protease activity Total protease activity was measured using the
EnzChek protease assay kit, following the manufacturer's instructions
(Molecular Probes). STI, BBI, and soymilk were diluted in digestion
buffer and incubated at 1:1 (vol/vol) with 1000 units of trypsin, prepared
in digestion buffer. Following incubation with BODIPY ¯uorescent
casein substrate at room temperature for 1 h, ¯uorescence was measured
(excitation 505/emission 515) on a SpectraMax Gemini microtiter plate
reader (Molecular Devices) using Softmax Pro 3.0 software (Molecular
Devices). Each experiment was performed in six replicates and was
repeated three times. The percentage inhibition of trypsin cleavage of the
substrate by STI, BBI, or soymilk was calculated using Microsoft Excel
and graphed in Sigma Plot.
PAR-2 cleavage assay A synthetic peptide comprising the cleavage
site of the human PAR-2, SKGRSLIGK (Lourbakos et al, 1998), was
labeled with the ¯uorophore pair Edans/Dabsyl (Advanced Bioconcept,
Montreal, Canada), and was used as a substrate for PAR-2 serine
protease activators. Cleavage of this peptide with PAR-2 activators such
as trypsin could be detected ¯uorescently (excitation 335/emission 515).
The inhibition of trypsin-induced PAR-2 peptide cleavage by STI, BBI,
or soymilk was measured by incubating 100 mM peptide with 10 units of
trypsin [in 100 mM Tris(hydroxymethyl)aminomethane buffer, pH 8.0,
Digene, Beltsville, MD], with or without the test material, for 1 h at
room temperature, protected from light. Fluorescence was measured on
SpectraMax Gemini microtiter plate reader (Molecular Devices) using
Softmax Pro 3.0 software (Molecular Devices). Each experiment was
performed in six replicates and was repeated three times. The percentage
inhibition of trypsin cleavage was calculated using Microsoft Excel and
graphed in Sigma Plot.
RESULTS
STI and BBI reduce pigment deposition in vitro Our
previous studies demonstrated that the PAR-2 pathway affects
pigmentation via keratinocyte±melanocyte interactions (Seiberg et
al, 2000a). Treatment with the serine protease inhibitor RWJ-
50353, a trypsin and thrombin inhibitor (Costanzo et al, 1996),
resulted in decreased pigmentation in vitro and in vivo (Seiberg et al,
2000b). The studies described here were designed to examine the
possibility that serine protease inhibitors from natural sources could
also affect pigmentation by inhibiting the PAR-2 pathway.
Consequently, keratinocyte±melanocyte cocultures were treated
for 72 h with the two soybean-derived serine protease inhibitors,
STI and BBI (0.1%). Cocultures were DOPA stained (Fig 1a, b)
and images of the stained cultures were analyzed for their relative
level of pigmentation (Fig 1c). As shown in Fig 1(b), STI treated
cocultures demonstrate reduced tyrosinase activity relative to
untreated controls (Fig 1a), as indicated by the DOPA staining.
Similar results were obtained for BBI, as quanti®ed in Fig 1(c).
These results indicate that both STI and BBI could induce
lightening of melanocytes in keratinocyte±melanocyte cocultures.
In addition, skin equivalents containing melanocytes were treated
with STI and BBI for 72 h and histologic sections were stained
Figure 4. STI reduces pigment deposition in grafted human skin.
Human skins grafted on SCID mice were treated with STI (1%) for 9
wk and histologic sections of vehicle control (a) and STI treated (b) skin
samples were stained with F&M. Scale bar: 10 mm. STI treatment results
in reduced pigmentation at both the basal and suprabasal layers, and
melanin caps are reduced or eliminated.
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with F&M, documenting melanin deposition within the
equivalents. Figure 2(a)±(c) demonstrates decreased pigment
deposition in this three-dimensional epidermal equivalents system
following STI or BBI treatment. A computerized image analysis of
the F&M stained sections (Fig 2d) shows about 50% and 25%
reduction in melanin deposition following STI and BBI treatment,
respectively. Interestingly, STI was also shown to prevent UVB -
induced pigmentation in epidermal equivalents, when applied
immediately after UVB exposure. Figure 2(d) shows an increase in
pigment deposition (relative to untreated controls) following one
exposure to UVB irradiation (100 mJ per cm2). A complete
inhibition of this UVB-induced pigmentation and a further
decrease in pigmentation relative to the control were observed
when the UVB exposure was followed with 0.1% STI treatment
for 3 d.
STI and BBI reduce pigmentation in vivo Dark skinned
Yucatan microswine were topically treated with STI or BBI (1%,
5%, and 10%, in GDL liposomes), twice daily, for 8 or 9 wk. A
visible whitening effect was observed starting at the fourth or ®fth
week, at the sites treated with the highest STI concentration. By
the eighth week all STI (Fig 3a) and BBI (not shown) treated sites
exhibited lighter skin color, with a saturation effect for the two
highest doses. Histologic analysis of skin biopsies taken at the eighth
or ninth week of treatment and stained with F&M further
con®rmed the depigmenting effect of STI and BBI (Fig 3b±d), as
pigment deposition was dramatically reduced in the treated sites.
Occasionally, but not in all swine tested, some lightening was
observed at the liposomal vehicle treated site (Fig 3a). This
lightening effect was minimal, however, and not statistically
signi®cant. Figure 3(e) quanti®es this in vivo depigmenting effect
(average of six swine), demonstrating about 50% and 40% reduction
in pigment deposition following STI and BBI (1%) treatments,
respectively. To test the effectiveness of such treatments on human
skin, Afro-American pigmented skins were transplanted onto SCID
Figure 5. STI and soymilk affect PAR-2-
induced keratinocyte phagocytosis. HaCaT
keratinocytes were treated with SLIGRL (20 mM)
to activate PAR-2, with or without increasing
concentrations of STI or soymilk, followed by
incubation with ¯uorescently labeled E. coli
particles (a). An increase in ¯uorescence units
represents increased ingestion of the labeled
particles, as exogenous ¯uorescence was quenched
with trypan blue. All bars except the control
represent treatments with SLIGRL. Doses of the
additional treatments of STI or soymilk are
indicated below the bars. STI and soymilk
inhibition were statistically signi®cant (p < 0.001)
for all concentrations tested (p < 0.005 for the
two lowest doses of soymilk, t test, 6 standard
error). (b, c) STI induces cytoskeletal
reorganization, which is associated with reduced
phagocytic ability. HaCaT keratinocytes were
treated with STI as described and were stained
with rhodamine phalloidin to detect F-actin.
Reduced actin polymerization is observed
following STI treatment (c; compare to untreated
control b). (d)±(g) SEM analysis of control (d, f)
and STI treated (e, g) cells demonstrates a decrease
in cell podia number and length following STI
treatment. Scale bar: (d, e) 2.5 mm; (f, g) 0.25 mm.
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mice and were treated once daily for 9 wk with STI (1%, in 20 mg
per ml GDL liposomes). F&M stained sections of the STI treated
human skin demonstrate a visible decrease in pigment deposition,
relative to the untreated, same skin control (Fig 4a, b). These data
demonstrate that the soybean-derived proteins, STI and BBI, can
modulate pigmentation in vivo.
STI treatment affects keratinocyte phagocytosis The
inhibition of the PAR-2 pathway was shown to reduce
pigmentation by inhibiting melanosome transfer from
melanocytes to keratinocytes (Seiberg et al, 2000a, b). Sharlow et
al (2000) demonstrated that PAR-2 is involved in keratinocyte
phagocytosis, which mediates melanosome transfer. To examine
the possibility that STI could inhibit PAR-2 -induced keratinocyte
phagocytosis, HaCaT keratinocytes were treated with SLIGRL, a
PAR-2 activating peptide, and increasing concentrations of STI for
24 h, followed by incubation with ¯uorescent-labeled E. coli K-12
bioparticles for 4 h. Intracellular ¯uorescence, indicative of ingested
E. coli particles, was measured after trypan blue quenching of the
noninternalized ¯uorescence. As shown in Fig 5(a), SLIGRL
increased keratinocyte phagocytosis by about 5-fold, and STI
prevented this increase in a dose-dependent manner. Interestingly,
freshly prepared soymilk was able to inhibit SLIGRL -induced
phagocytosis in keratinocytes to a similar degree. As phagocytosis
involves actin polymerization and cytoskeletal reorganization, the
possibility that STI treatment results in actin reorganization was
examined. Keratinocytes were treated with STI or BBI for 48 h
and stained with rhodamine phalloidin to visualize ®lamentous
actin. STI (Fig 5c) and BBI (not shown) treatments result in
decreased actin polymerization, in particular at the core region
proximal to the plasma membrane, compared with untreated
controls (Fig 5b). PAR-2 activation was shown earlier to induce
distinct cell surface changes, and in particular increased number and
length of cell projections, that were correlated with the
keratinocytes' increased phagocytic ability (Sharlow et al, 2000).
To test the hypothesis that STI could induce the opposite changes,
STI treated keratinocytes were examined using electron
microscopy. Figure 5(d)±(g) shows SEM pictures of untreated (d,
f) and STI treated (e, g) keratinocytes, demonstrating reduced
number and length of cell podia following STI treatment. These
results support the idea that STI reduces pigment deposition in skin
by reducing keratinocyte phagocytosis and that it might be possible
to use soybean extracts containing STI such as soymilk for skin
depigmentation.
STI and soymilk could affect PAR-2 activation To further
assess the possibility that STI and soymilk affect the PAR-2
pathway by inhibiting PAR-2 activation, an enzyme inhibition
study was performed. First, STI and soymilk were shown to inhibit
trypsin-induced cleavage of a ¯uorescent casein peptide in a dose-
dependent manner (Fig 6a). Second, a similar assay was designed to
test the possible speci®c inhibition of these agents on PAR-2
cleavage. In this assay, a synthetic ¯uorescent peptide comprising
the cleavage site of the human PAR-2, SKGRSLIGK (Lourbakos et
al, 1998), replaced the casein peptide as a substrate for trypsin. As
shown in Fig 6(b), the cleavage of this peptide by trypsin was
completely inhibited in the presence of STI. Soymilk retained the
ability to inhibit this trypsin-induced PAR-2 cleavage (Fig 6b),
suggesting that, similar to STI, soybean extracts could inhibit PAR-
2 activation.
Soybean extracts reduce pigmentation in vivo To test the
hypothesis that soybean extracts can induce skin depigmentation,
dark skinned Yucatan microswine were topically treated for 8 wk
with STI (in GDL liposomes), soymilk, and soybean paste.
Reduced skin color was observed visually (e.g., soymilk, Fig 7a),
and depigmentation was con®rmed by F&M staining of histologic
sections (see Fig 7b±e). Both soymilk (Fig 7d) and soybean paste
(Fig 7e) reduced melanin deposition within the swine epidermis
similar to STI (Fig 7c). Interestingly, heat denatured soymilk
(100°C, 10 min) had minimal or no depigmenting activity on the
swine skin (Fig 7f) or in vitro (not shown). Similarly, commercially
available pasteurized soymilk preparations like the baby formula
Similac had no depigmenting activity (not shown) suggesting that a
heat labile component of the soymilk is one of the active
depigmenting agents. It is important to note that, whereas STI
required a liposomal delivery system to enable penetration and
activity, the soybean extracts did not require the addition of any
delivery vehicle to exert their depigmenting activity.
Soymilk and STI can prevent UVB-induced pigmentation
in vivo Figure 2(e) demonstrates that STI can prevent UVB-
induced pigmentation in epidermal equivalents containing
melanocytes. To examine whether STI and soymilk could inhibit
UVB-induced pigmentation in vivo, lighter skinned Yucatan
microswine were UVB irradiated with one MED, three times
during 1 wk, to create a visible tanning response. UVB-irradiated
sites were treated daily, for 10 d, either immediately after UVB
exposure or on non-UVB-exposure days, and the level of tanning
was monitored. Treatment with UVB alone or UVB and vehicle
induced visible darkening, which was con®rmed histologically
using F&M staining (compare Fig 8b, UVB and vehicle treatment,
with the untreated skin shown in Fig 8a). Treatments with soymilk
(Fig 8c), or STI (not shown), prevented this UVB-induced
darkening. Image analysis of F&M stained sections quanti®es this
effect (Fig 8d), further supporting the notion that STI and soymilk
could prevent UVB-induced tanning.
Figure 6. Soymilk and STI inhibit trypsin-induced peptide
cleavage. (a) A ¯uorescent casein peptide was incubated with trypsin, in
the presence of increasing concentrations of STI and soymilk, as
described in Materials and Methods. STI and soymilk inhibited trypsin
digestion in a dose-responsive manner (p < 0.001, t test, 6 standard
error). (b) A synthetic ¯uorescent peptide comprising the cleavage site of
the human PAR-2, SKGRSLIGK, was used as a substrate for trypsin in a
similar system. Cleavage of this peptide by trypsin was inhibited in the
presence of STI or soymilk (p < 0.001, t test, 6 standard error).
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DISCUSSION
The epidermal-melanin unit, a functional unit that produces and
distributes melanin (reviewed in Ortonne, 1995) was shown to
have a role in the regulation of pigmentation. We had shown that
serine protease inhibitors that interfere with activation of the
keratinocyte receptor PAR-2 induce depigmentation by affecting
melanosome transfer (Seiberg et al, 2000a, b). Modulation of the
PAR-2 pathway with serine protease inhibitors such as RWJ-
50353 was suggested as an alternative to depigmenting therapies.
Here we show that soymilk could be used as a natural, safe, and
ef®cacious depigmenting agent. STI and BBI, the soybean-derived
serine protease inhibitors, are shown to inhibit PAR-2 activation,
which leads to reduced pigment production and skin lightening.
Interestingly, soymilk and STI could also prevent UV-induced
pigmentation, demonstrating the importance of melanosome
transfer in the regulation of the tanning response.
Human skin expresses a number of serine proteases under both
physiologic and in¯ammatory conditions (FraÈki et al, 1983). These
serine proteases are involved in the degradation of extracellular
proteins, as well as in generating active peptides that trigger
intracellular signaling (reviewed in Hollenberg et al, 1996).
Coughlin and colleagues identi®ed a group of receptors activated
by serine protease cleavage and unmasking of a tethered ligand. Of
the four protease-activated receptors known to date (Vu et al, 1991;
Nystedt et al, 1995a; Ishihara et al, 1997; Xu et al, 1998), PAR-2 is
the only one found to affect pigmentation. PAR-2 has been
implicated in the inhibition of keratinocyte growth and differen-
tiation (Derian et al, 1997) but its natural activators in skin remain
to be identi®ed. The expression of trypsin, a known activator of
PAR-2, was identi®ed in skin (Koshikawa et al, 1998), but a direct
link of trypsin to PAR-2 activation in skin has not been
investigated.
We suggest that soymilk exerts its depigmenting effect by the
inhibition of PAR-2 activation in skin. STI and BBI inhibit PAR-2
activation, reduce keratinocyte phagocytosis, and induce skin
lightening. Soymilk is also shown to inhibit trypsin-induced PAR-
2 cleavage in vitro, to affect keratinocyte phagocytosis, and to
reduce skin pigmentation in swine. Preliminary Western blots, high
performance liquid chromatography, and immuno¯uorescence data
(not shown) indicate that the soymilk preparations used for topical
treatment contain intact STI, and that STI could be detected in the
treated swine skin immunologically. Taken together, we suggest
that the depigmenting effect of soymilk is due, in part, to the
inhibition of the PAR-2 pathway by STI.
STI and BBI are not the only components in soymilk that could
induce skin lightening. In addition to protein protease inhibitors,
soybeans contain trace amounts of free fatty acids and their acyl
CoA esters, which have been reported to inhibit trypsin (Liu et al,
1990) and could possibly add to the inhibition of the PAR-2
pathway. Soybeans contain iso¯avones, recently shown to have a
role in prevention and treatment of vascular and cancerous diseases
Figure 7. Soymilk and soybean extract
reduce pigmentation in vivo. Dark skinned
Yucatan swine were treated daily, for 8 or 9 wk,
with STI and soybean products. A visual
whitening effect was observed on the STI,
soymilk, and soybean paste treated sites (a, a site
on the swine's ¯ank treated with soymilk). F&M
staining of skin biopsies from the treated sites
demonstrates reduced pigment deposition
following STI (c, 1%), soymilk (d), and soybean
paste (e) treatments, relative to the untreated sites
(b). Heat denatured soymilk (f, 100°C, 10 min)
failed to reduce pigment deposition in the swine
skin. Scale bar: 10 mm.
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(e.g., Lichtenstein, 1998; Tham et al, 1998; Anderson et al, 1999).
Iso¯avones possess antioxidant activity (Fleury et al, 1992), which
could reduce melanogenesis by affecting the DOPA oxidase activity
of tyrosinase, the rate-limiting enzyme in melanin biosynthesis
(reviewed in Pawelek and Charkraborty, 1998). Soybeans contain
phospholipids, sometimes referred to as ``soy lecithins''.
Phospholipids comprise the major components of the cell mem-
brane, and are used as emulsifying agents (reviewed in Liu, 1999).
We speculate that it is the soybean phospholipids that enable STI
and BBI delivery into the skin, without the aid of liposomes, when
whole soymilk is used for topical treatment.
Soybeans were used in Asia, during the Chou Dynasty (1134±
246 BC), as a crop rotation material, but soy products were not
served as food until precipitation and fermentation techniques were
developed. The Chinese did not eat soybeans because of ``harmful
substances'' that produced serious gastric distress. These harmful
substances are the potent serine protease inhibitors, STI and BBI,
which block the action of trypsin and other proteases needed for
protein digestion. It is the heat inactivation of STI and BBI during
soybean processing (reviewed in Wallace et al, 1971; Kwok and
Niranjan, 1995) that renders the soybean-derived nutrition
products inactive as depigmenting agents. We showed that fresh
soymilk, but not heat-denatured or pasteurized soymilk, could
exert depigmenting effects in vivo. As STI is heat labile, but BBI is
less affected by heat (Birk, 1985; Liu, 1999), it is more likely that
STI is the major depigmenting agent in soymilk.
The inhibition of the PAR-2 pathway by soymilk and the
soybean-derived serine protease inhibitors STI and BBI results in
skin depigmentation. The soymilk-induced depigmenting effect is
reversible and daily topical treatments for 7 mo result in no visual or
histologic negative effect (not shown). The depigmenting activity
of STI, BBI, and soymilk, as well as their ability to prevent UV-
induced pigmentation, correlate with PAR-2 cleavage, with
cytoskeletal and cell surface reorganization, and with reduced
keratinocyte phagocytosis. As shown for other serine protease
inhibitors (Seiberg et al, 2000a), soymilk induces depigmentation
only when keratinocyte±melanocyte contact is established (data not
shown) and has no pigmentary effect on melanocytes alone.
Clinical studies carried out based on our observations showed
signi®cant human skin lightening after a 3 wk treatment with a
soybean extract containing intact STI (Hermanns et al, 2000).
These data suggest that the inhibition of the PAR-2 pathway by
soymilk could be used as a natural alternative to skin lightening.
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